These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 39030528)

  • 1. Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis.
    Hou M; Luo X; He S; Yang X; Zhang Q; Jin M; Zhang P; Li Y; Bi X; Li J; Cheng C; Xue Q; Xing H; Liu Y
    J Headache Pain; 2024 Jul; 25(1):116. PubMed ID: 39030528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atogepant for the Preventive Treatment of Migraine.
    Ailani J; Lipton RB; Goadsby PJ; Guo H; Miceli R; Severt L; Finnegan M; Trugman JM;
    N Engl J Med; 2021 Aug; 385(8):695-706. PubMed ID: 34407343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.
    Singh A; Balasundaram MK
    Clin Drug Investig; 2022 Apr; 42(4):301-308. PubMed ID: 35230651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.
    Rizzoli P; Marmura MJ; Robblee J; McVige J; Sacco S; Nahas SJ; Ailani J; De Abreu Ferreira R; Ma J; Smith JH; Dabruzzo B; Ashina M
    J Headache Pain; 2024 Mar; 25(1):35. PubMed ID: 38462625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials.
    Gui T; Li H; Zhu F; Wang Q; Zhou X; Xue Q
    Headache; 2022 Nov; 62(10):1281-1292. PubMed ID: 36373822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
    Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
    Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term efficacy and safety of lasmiditan, a novel 5-HT
    Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
    J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.
    Hou M; Xing H; Cai Y; Li B; Wang X; Li P; Hu X; Chen J
    J Headache Pain; 2017 Dec; 18(1):42. PubMed ID: 28389966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials.
    Yang Y; Chen M; Sun Y; Gao B; Chen Z; Wang Z
    CNS Drugs; 2020 May; 34(5):463-471. PubMed ID: 32193827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety.
    Lattanzi S; Trinka E; Altamura C; Del Giovane C; Silvestrini M; Brigo F; Vernieri F
    Neurol Ther; 2022 Sep; 11(3):1235-1252. PubMed ID: 35705886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial.
    Goadsby PJ; Friedman DI; Holle-Lee D; Demarquay G; Ashina S; Sakai F; Neel B; Gandhi P; Dabruzzo B; Smith JH; Liu Y; Trugman JM
    Neurology; 2024 Jul; 103(2):e209584. PubMed ID: 38924724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis.
    Sun W; Cheng H; Xia B; Liu X; Li Y; Wang X; Liu C
    Clin J Pain; 2023 Oct; 39(10):560-569. PubMed ID: 37278480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial.
    Tassorelli C; Nagy K; Pozo-Rosich P; Lanteri-Minet M; Sacco S; Nežádal T; Guo H; De Abreu Ferreira R; Forero G; Trugman JM
    Lancet Neurol; 2024 Apr; 23(4):382-392. PubMed ID: 38364831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atogepant: an emerging treatment for migraine.
    Rustichelli C; Avallone R; Ferrari A
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.
    Tao X; Yan Z; Meng J; Wang W; Dai Q; Zhou Q; Wang Z; Wang Z
    J Headache Pain; 2022 Jan; 23(1):19. PubMed ID: 35093013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The preclinical discovery and development of atogepant for migraine prophylaxis.
    Baraldi C; Beier D; Martelletti P; Pellesi L
    Expert Opin Drug Discov; 2024 Jul; 19(7):783-788. PubMed ID: 38856039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR; da Silva MRR
    Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
    Haghdoost F; Puledda F; Garcia-Azorin D; Huessler EM; Messina R; Pozo-Rosich P
    Cephalalgia; 2023 Apr; 43(4):3331024231159366. PubMed ID: 36855951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.